Literature DB >> 31787537

Overall survival with osimertinib in untreated NSCLC.

Elizabeth Gourd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31787537     DOI： 10.1016/S1470-2045(19)30778-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

1.  Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.

Authors:  Burak Bilgin; Mehmet Ali Nahit Sendur; Sebnem Yucel; Emir Celik; Deniz Tataroglu Ozyukseler; Murat Ayhan; Tugba Basoglu; Aysegul Ilhan; Nadiye Akdeniz; Ahmet Gulmez; Izzet Dogan; Burak Yasin Aktas; Mustafa Gurbuz; Sinan Koca; Semra Paydas; Ali Murat Tatli; Havva Yesil Cinkir; Ozkan Alan; Cihan Erol; Mutlu Hizal; Engin Kut; Serkan Menevse; Teoman Sakalar; Halil Taskaynatan; Gulhan Ipek Deniz; Mustafa Karaagac; Okan Avci; Erdem Sen; Fatih Karatas; Muhammed Bulent Akinci; Didem Sener Dede; Atakan Demir; Ahmet Demirkazık; Berna Oksuzoglu; Sadettin Kilickap; Fulden Yumuk; Bulent Yalcin
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-12       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.